Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine

British Journal of Pharmacology

Volumn 157, Issue 5, 2009, Pages 831-843

  Ding, Zhe ^a   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Analgesia (antinociception); Buprenorphine; Mechanism of action; Supraspinal

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BUPRENORPHINE; FENTANYL; GZ PROTEIN ANTISENSE; MORPHINE SULFATE; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NALOXONE; NOCICEPTIN; OKADAIC ACID; PERTUSSIS TOXIN; PHOSPHATASE; SERINE; SERINE THREONINE PROTEIN PHOSHATASE; UNCLASSIFIED DRUG; YOHIMBINE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ADRENERGIC ALPHA-ANTAGONISTS; AMINOQUINOLINES; ANALGESICS, OPIOID; ANESTHETICS, LOCAL; ANIMALS; BENZAMIDES; BRAIN; BUPRENORPHINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FENTANYL; GTP-BINDING PROTEINS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MICE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; OKADAIC ACID; OLIGONUCLEOTIDES, ANTISENSE; OPIOID PEPTIDES; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PERTUSSIS TOXIN; PHOSPHOPROTEIN PHOSPHATASES; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, OPIOID; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; YOHIMBINE;

EID: 70350176184     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00209.x     Document Type: Article

References (85)

1. Ahlgren S, Levine JD (1994). Protein kinase C inhibitors decrease hyperalgesia and C-flber hyperexcitability in the streptozotocindiabetic rat. J Neurophysiol 72: 684-692. (Pubitemid 24273574)
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Bentley KW, Hardy DG (1967). Novel analgesics and molecular rearrangements in the morphine-thebalne group. III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and - norcodeine. J Am Chem Soc 89: 3281-3292.
4. Bentley KW, Hardy DG, Meek B (1967). Novel analgesics and molecular rearrangements in the morphine-thebaine group. II. Alcohols derived from 6,14-endoetheno- and 6,14endoethenotetrahydrothebaine. J Am Chem Soc 89: 3273-3280.
5. Bernstein MA, Welch SP (1998). Inhibition of protein phosphatases alters the expression of morphine tolerance in mice. Eur J Pharmacol 341: 173-177. (Pubitemid 28131113)
6. Bialojan C, Takai A (1988). Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256: 283-290. (Pubitemid 18273473)
7. Blake AD, Bot G, Freeman JC, Reisine T (1997). Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem 272: 782-790. (Pubitemid 27034564)
8. Boas RA, Villiger JW (1985). Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 57: 192-196.
9. Budd K (1981). High dose of buprenorphine for postoperative analgesia. Anaesthesia 36: 900-903. (Pubitemid 11008463)
10. Budd K, Raffa RB (2005). Buprenorphine-the Unique Opioid Analgesic: Pharmacology and Clinical Application. Thieme: New York.
11. 16 proteins. J Neurochem 71: 2203-2210.
12. Chen MX, Mcpartlin AE, Brown L, Chen YH, Barker HM, Cohen PT (1994). A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. Eur MoI Biol Org J 13: 4278-4280.
13. Christoph T, Kögel B, Schiene K, Méen M, De Vry J, Friderichs E (2005). Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507: 87-98. (Pubitemid 40126844)
14. Cohen PT (1997). Novel protein serine/threonine phosphatases: variety is the spice of life. Trends Biochem Sci 22: 245-251.
15. Collier HOJ, Dinneen LC, Johnson CA, Schneider C (1968). The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol 32: 295-310.
16. Cowan A (1995). Update on the general pharmacology of buprenorphine. In: Cowan A, Lewis JW (eds). Buprenorphine: Combatting Drug Abuse with a Unique Opioid. Wiley-Liss: New York, pp. 31-47.
17. Cowan A, Lewis JW (1995). Buprenorphine: Combatting Drug Abuse with a Unique Opioid. Wiley-Liss: New York.
18. Dahan A (2005). New insights into buprenorphine's respiratory effects. In: Budd K, Raffa RB (eds). Buprenorphine-The Unique Opioid Analgesic: Pharmacology and Clinical Application. Thieme: New York, pp. 22-32.
19. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L et al. (2005). Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94: 825-834. (Pubitemid 40754001)
20. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L et al. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96: 627-632.
21. Dum JE, Herz A (1981). In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 74: 627-633.
22. Gabra BH, Bailey CP, Kelly E, Sanders AV, Henderson G, Smith FL et al. (2007). Evidence for an important role of protein phosphatases in the mechanism of morphine tolerance. Brain Res 1159: 86-93. (Pubitemid 47058027)
23. Garzón J, Castro M, Sanchez-Blazquez P (1998). Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to mu receptors. Eur J Neurosci 10: 2557-2564. (Pubitemid 28362563)
24. Garzón J, de Antonio I, Sánchez-Blázquez P (2000). In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides. Methods Enzymol 314: 3-20.
25. Ge Z-j, Zeng Y-m, Tan Y-f (2005). Effects of intrathecal 6-hydroxydopamine, α1 and α2 adrenergic receptor antagonists on antinociception of propofol in mice. Acta Pharmacol Sin 26: 186-191. (Pubitemid 40203964)
26. George SR, Fan T, Xie Z, Tse R, Tarn V, Varghese G et al. (2000). Oligomerization of μ- and δ-opiold receptors. J Biol Chem 275: 26128-26135.
27. Gilbert AK, Franklin KBJ (2002). The role of descending fibers from the rostral ventromedial medulla in opioid analgesia in rats. Eur J Pharmacol 449: 75-84.
28. Greenwald MK, Johanson C-E, Moody DE, Woods JH, Kilboum MR, Koeppe RA et al. (2003). Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28: 2000-2009.
29. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE et al. (2007). An opioid agonist that does not induce u-opioid receptor - arrestin interactions or receptor internalization. Mot Pharmacol 71: 549-557. (Pubitemid 46147920)
30. Haley TJ, McCormick WG (1957). Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12: 12-15.
31. Hastie CJ, Cohen PT (1998). Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. Fed Eur Biochem Soc Lett 431: 357-361.
32. Haystead TAJ, Sim ATR, Carling D, Honnor RC, Tsukitani Y, Cohen P et al. (1989). Effects of the tumour promoterokadaic acid onintracellular protein phosphorylation and metabolism. Nature 337: 78-81. (Pubitemid 19022553)
33. Ho MK, Wong YH (1998). Structure and function of the pertussistoxin- insensitive Gz protein. Biol Signals Recept 7: 80-89.
34. Honkanen RE (1993). Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 330: 283-286. (Pubitemid 23276340)
35. Honkanen RE, Golden T (2002). Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem 9: 2055-2075.
36. Huang X, Honkanen RE (1998). Molecular cloning, expression, and characterization of a novel human serine-threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degenration C gene product (rdgC). J Biol Chem 273: 1462-1468. (Pubitemid 28133667)
37. Huang P, Kehner GB, Cowan A, Liu-Chen L-Y (2001). Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297: 688-695. (Pubitemid 32378001)
38. Hylden JL, Wilcox GL (1980). Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67: 313-316. (Pubitemid 10007057)
39. Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K (2004). Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu opioid receptor knockout mice. Neuropsychopharmacology 29: 1656-11563
40. Institute of laboratory Animal Resources (1996). Guide for the Care and Use of Laboratory Animals, 7th edn. Institue of Laboaratory Animal Resources, Commission on Life Sciences, National Research Council: Washington DC.
41. Janssen PAJ, Niemegeers CJE, Dony JGH (1963). The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneim Forsch 13: 502-507.
42. zα on antinociception produced by spinal opioid and 012 adrenergic receptor agonists. Pain 87: 181-191.
43. Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F et al. (2007). SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/μ-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 320: 934-943. (Pubitemid 46147978)
44. Kosterlitz HW, Leslie FM, Waterfield AA (1975). Rates of onset and offset of action of narcotic analgesics in isolated preparations. Eur J Pharmacol 32: 10-16.
45. Lee K, Akil H, Woods JH, Traynor JR (1999). Novel binding properties of oripavines at a cloned mu opioid receptor. Eur f Pharmacol 378: 323-330.
46. Li YM, Casida JE (1992). Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sei USA 89: 11867-11870.
47. Li YM, MacKintosh C, Casida JE (1993). Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site Inhibitor specificity of cantharidan and ATP analogues. Biochem Pharmacol 46: 1435-1443.
48. Liu JG, Anand KJ (2001). Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Rev 38: 1-19.
49. Lutfy K, Cowan A (2004). Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2: 395-402. (Pubitemid 39276631)
50. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W et al. (2003). Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23: 10331-10337. (Pubitemid 37444610)
51. Maeda T, Hamabe W, Gao Y, Fukazawa Y, Kumamoto K, Ozaki M et al. (2005). Morphine has an antinociceptive effect through activation of the okadaic-acid-sensitive Ser/Thr protein phosphatases PP2A and PP5 estimated by tall-pinch test in mice. Brain Res 1056: 191-199. (Pubitemid 41557707)
52. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976). The effect of morphine and nalorphine-like drugs in the non-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517-532.
53. Mogil JS, Pasternak GW (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53: 381-415.
54. Moneada A, Cendán CM, Baeyens JM, Del Pozo E (2003). Effects of serine/threonine protein phosphatase inhibitors on morphineinduced antinociception in the tail flick test in mice. Eur J Pharmacol 465: 53-60.
55. B but not κ-opioid receptors in the tail flick test in mice. Pain 114: 212-220.
56. Morgan D, Cook CD, Smith MA, Picker MJ (1999). An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. Anesth Analg 88: 407-413. (Pubitemid 29070208)
57. Neilan CL, Husbands SM, Breeden S, Ko MC, Aceto MD, Lewis JW et al. (2004). Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur J Pharmacol 499: 107-116. (Pubitemid 39201217)
58. Ocaña M, Entrena JM, Baeyens JM, Del Pozo E (2007). The antinociceptive effect of morphine is reversed by okadaic acid in morphinenaïve but not morphine-tolerant mice. Pharmacol Biochem Behav 86: 21-26. (Pubitemid 46274965)
59. Parolaro D, Patrini G, Giagnoni G, Massi P, Groppetti A, Parenti M (1990). Pertussis toxin inhibits morphine analgesia and prevents opiate dependence. Pharmacol Biochem Behav 35: 137-141. (Pubitemid 20034578)
60. Pasternak GW (1993). Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16: 1-18.
61. Price NE, Mumby MC (1999). Brain protein serine/threonine phosphatases. Curr Opin Neurobiol 9: 336-342.
62. Raffa RB, Martinez RP, Connelly CD (1994). G-protein anti-sense oligodeoxy-ribonucleotides and μ-opioid supraspinal antinociception. Eur I Pharmacol 258: R5-R7. (Pubitemid 2095555)
63. Raffa RB, Ding Z (2007). Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partialagonist. Acute Pain 9: 145-152.
64. Rance MJ, Lord JAH, Robinson T (1980). Biphasic dose response to buprenorphine in the rat tail flick assay: effect of naloxone pretreatment. In: Way EL (ed.). Endogenous and Exogenous Opiate Agonists and Antagonists. Pergamon Press: New York, pp. 387-390.
65. Rizzi A, Nazzaro C, Marzola GG, Zucchini S, Trapella C, Guerrini R et al. (2006). Endogenouis nociceptin/orphanin FQ signaling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidence. Pain 124: 100-108. (Pubitemid 44176199)
66. Rothman RB, Ni Q, Xu H (1995). Buprenorphine: a review of the binding literature In: Cowan A, Lewis JW (eds). Buprenorphine: Combatting Drug Abuse with a Unique Opioid. Wiley-Liss: New York 19-29.
67. Sadée W, Rosenbaum JS, Herz A (1982). Buprenorphine: differential Interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223: 157-162. (Pubitemid 12033828)
68. Sánchez-Blázquez P, Gómez-Serranillos P, Garzón J (2001). Agonists determine the pattern of G-protein activation in μ-opioid receptormediated supraspinal analgesia. Brain Res Bull 54: 229-235.
69. 3sS]GTPTS binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285: 496-505.
70. Shinkai H, Ito T, lida T, Kitao Y, Yamada H, Uchida I (2000). 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J Med Chem 43: 4667-4677.
71. Standifer KM, Rossi GC, Pasternak GW (1996). Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits. MoI Pharmacol 50: 293-298.
72. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L et al. (1998). Standard binding and fiunctional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466.
73. Traynor JR (2004). G-protein coupling and efficacy of μ-opioid agonists: relationship to behavioral efficacy. Revs Analgesia 8: 11-22.
74. 3SS]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. MoI Pharmacol 47: 848-854.
75. Tso PH, Yung LY, Wong YH (2000). Regulation of adenylyl cyclase, ERK1/2, and CREB by Gz following acute and chronic activation of the delta-opioid receptor. J Neurochem 74: 1685-1693. (Pubitemid 30163991)
76. Vanderah TW, Raffa RB, Lashbrook J, Burritt A, Hruby V, Porreca F (1998). Orphanin-FQ/nociceptin: lack of antinociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. Eur J Pain 2: 267-280.
77. Villiger JW, Taylor KM (1981). Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 29: 2699-2708.
78. Wang ZJ, Wang LX (2006). Phosphorylation: a molecular switch in opioid tolerance. Life Sci 79: 1681-1691.
79. Wheeler-Aceto H, Cowan A (1991). Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol 195: 411-413.
80. Wnendt S, Krüger T, Janocha E, Hildebrandt D, Englberger W (1999). Agonist effect of buprenorphine in a nociceptin/OFQ receptortriggered reporter gene assay. MoI Pharmacol 56: 334-338. (Pubitemid 29347609)
81. Womer DE, DeLapp NW, Shannon HE (1997). Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain 70: 223-228.
82. Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K (2002). Pharmacological profiles of a novel opioid receptor-like1 (ORL1) receptor antagonist, JTC-801. Br J Pharmacol 135: 323-332. (Pubitemid 34151164)
83. Yamamoto T, Shono K, Tanabe S (2006). Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther 318: 206-213. (Pubitemid 43920757)
84. Yu YK, Zhang L, Yin XX, Sun H, Uhl GR, Wang JB (1997). Mu-opioid receptor phosphorylation, desensitization, and iigand efficacy. J Biol Chem 272: 28869-28874.
85. Zhang R, Nagata T, Hayashi T, Miyata M, Kawakami Y (2004). Intracerebroventricular injection of trazodone produces 5-HT receptor subtype mediated anti-nociception at the supraspinal and spinal levels. Eur Neuropsychopharmacol 14: 419-424. (Pubitemid 39141685)